Facts of the case:
• You are a potential investor in an “ultra-orphan drug” called AZD targeting tumors in young children.
• There are two tumor types – A&B – that AZD targets
• AZD is not a cure, but will extend the life of a child with tumor type A or B by ten years, enabling the child to survive with a high quality of life while awaiting a potential cure.
• A child is given a one dose injection of AZD in his/her lifetime.
• In any given year, there are 5,000 cases of A and 20,000 cases of B in the country.
• An ultra-orphan drug is defined as having fewer than 50,000 patients in any year.
• All children with tumor types A&B currently die, as there are no drugs or therapies available.
• The U.S Food and Drug Administration (FDA) encourages – through more flexible rules and “fast-track” procedures – companies to develop ultra-orphan drugs for these very small markets that they serve.
• Using the tools that we have studied and utilized throughout the course and in earlier presentations, prepare the following PowerPoint charts:
• FIVE FORCES – Industry Analysis
• SWOT – Company Analysis for AZD
• DQ Spider – Strategy Analysis
• Congruence – Implementation Analysis
• Recommendation – Invest or Do Not Invest
Sample Solution